Astellas, a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products, acquired Cambridge, Massachusetts biotechnology firm Potenza Therapeutics for $225m. "This transaction underscores Astellas' commitment to innovation and scientific partnerships to advance our creation of value for patients," said Kenji Yasukawa, Ph.D., President and CEO, Astellas. "In oncology, Astellas has focused on developing treatments for unmet medical needs with novel mechanisms of action and modalities. We believe the novel assets we have developed with Potenza have the potential to make an even more pronounced difference for patients in need."